期刊文献+

奥美沙坦酯杂质A和C的合成

Syntheses of Impurity A and C of Olmesartan Medoxomil
暂未订购
导出
摘要 目的:优化和改进奥美沙坦酯杂质A和C的合成反应条件,提供了一条简单实用的合成奥美沙坦酯杂质A和C杂质对照品的路线。方法:杂质A由原料1通过一步酸解脱除三苯甲基保护基,然后用丙酮重结晶得到,而杂质C则通过原料2经叔醇官能团脱水成双键和酸解脱除三苯甲基保护基两步反应,最后通过柱层析得到。结果:优化了反应条件,重现性好,纯度大于95%符合杂质对照品要求。结论:本方法反应方法操作简单实用,重现性好。 Objective: A synthetic method towards impurity A and C of olmesartan medoxomil has been pro-vided through optimizing literature reaction conditions. Methods: Impurity A was directly obtained by acidic-removal of Trt protecting group of starting material 1 with subsequent recrystallization from acetone, whereas impurity C was afforded through dehydration of tertiary alcohol group of starting material 2 followed by acidic-removal of Trt protecting group. Results: Through optimization of literature reaction condition, impurity A and C with chemical purity greater than 95% can be readily obtained. Conclusion: The current method towards impurity A and C is simple and practical with good reproductivity.
出处 《药物资讯》 2016年第2期9-13,共5页 Pharmacy Information
  • 相关文献

参考文献4

二级参考文献62

  • 1李新生,葛健锋,胡晓春.弱碱作用下从叔醇简便地合成烯烃[J].有机化学,2005,25(6):727-729. 被引量:1
  • 2吴泰志,刘晓华,张福利,谢美华.抗高血压药奥美沙坦酯合成新路线和相关杂质的研究[J].药学学报,2006,41(6):537-543. 被引量:14
  • 3McConnaughey MM, McConnaughey JS. Considerations of the pharmacology of angiotensin receptor blockers [J]. J Clin Pharmacol,1999,39,547.
  • 4Mizuno M, Sada T, Ikeda M. Pharmacology of CS - 866,a novel nonpeptide angiotensin Ⅱ receptor antagonist [J]. Eur J Pharmacol,1995,285 (2) :181.
  • 5Schwocho LR, Masonson HN. Pharmacokinetics of CS - 866, a new angiotensin Ⅱ receptor blocker, in healthy subjects[J]. J Clin Pharmacol,2001,41 (5) :515.
  • 6Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction [J]. J Hypertens, 2001,19 (Suppl 1): 21.
  • 7Puchler K, Nussberger J, Laeis P. Blood pressure and endocrine effects of single doses of CS - 866, a novel angiotensin Ⅱ antagonist,in salt- restricted hypertensive patients[J]. J Hypertens. 1997,15(12 Part 2) :1809.
  • 8Kawaratani T, Puchler K, Laeis P, et al. Steady state pharmacokinetics of CS - 866, a novel angiotensin Ⅱ receptor antagonist in elderly and young hypertensive patients [J]. J Hum Hypertens. 1999,13(Suppl 3) :4.
  • 9Van Mieghem W A multicentre, double - blind, efficacy, tolerability and safety study of the oral angiotensin Ⅱ antagonist Olmesartan medoxomil versue atenolon in patients with mild to oderate essential hypertansion [J]. J Hypertens ,2001,19 (Suppl 2): 152.
  • 10Puchler K, Laeis P, Stumpe K O. A comparison of the efficacy and safety of the oral angiotersin Ⅱ - antagonist olmesartan medexomil with those of atenolol in patients with moderate to severe hypertensive under continuous treatments with hydrochlorothiazide [J]. J Hypertension ,2001,19 (Supple 2); 153.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部